Pharmacotherapeutics for Veterinary Dispensing

Name: Pharmacotherapeutics for Veterinary Dispensing
Brand: Wiley-Blackwell
Price: 131.99 EUR
Availability: OnlineOnly

Katrina L. Mealey(Herausgeber*in)

Wiley-Blackwell (Verlag)

1. Auflage

Erschienen am 5. Februar 2019

640 Seiten

E-Book

PDF mit Adobe-DRM

Systemvoraussetzungen

978-1-119-40455-2 (ISBN)

131,99 €inkl. 7% MwSt.

Systemvoraussetzungen

für PDF mit Adobe-DRM

E-Book Einzellizenz

Als Download verfügbar

Beschreibung

Delivers the foundational and practical knowledge required for pharmacists to become an integral part of the veterinary health care team, improving therapeutic outcome while preventing serious adverse drug reactions in veterinary patients

Pharmacotherapeutics for Veterinary Dispensing enables pharmacists and pharmacy students to expand the breadth of their pharmacological knowledge to include common veterinary species. The book offers a practical yet complete resource for dispensing drugs for canine and feline patients, with additional chapters on horses, birds, reptiles, small mammals, and food animals. Edited by a globally recognized expert in veterinary pharmacology, and including chapters written by veterinarians with expertise in pharmacotherapy and pharmacists with expertise in veterinary medicine, this book is designed to help pharmacists enhance the quality of veterinary patient care.

This book is the first to combine the expertise of both veterinarians and pharmacists to enable pharmacists to apply their knowledge and skills to assure optimal therapeutic outcomes for patients of all species. Pharmacotherapeutics for Veterinary Dispensing:

* Puts the information needed to safely dispense prescription and OTC drugs for veterinary patients at the pharmacists' fingertips

* Focuses on crucial details of canine and feline pharmacotherapeutics

* Helps pharmacists avoid adverse drug reactions including pharmacogenomic and breed-related drug sensitivities

* Offers an authoritative resource written by leading veterinary pharmacy experts designed to integrate pharmacists into the veterinary healthcare team

* Includes crucial regulatory information unique to veterinary drug dispensing and compounding

Pharmacotherapeutics for Veterinary Dispensing is an essential reference for all pharmacists and pharmacy students that might find themselves dispensing drugs to veterinary patients, as well as for veterinarians and others involved with dispensing veterinary drugs.

"Pharmacotherapeutics for Veterinary Dispensing is a book long overdue for the pharmacy profession....Whether you have practiced veterinary pharmacy your whole career or have never practiced veterinary pharmacy, this book has much to offer. Veterinarians are encouraged to suggest this book to pharmacists with whom they work and interact." - JAVMA Vol 255 No. 6

Weitere Details

Weitere Ausgaben

Inhalt

Intro
Title Page
Copyright Page
Contents
List of Contributors
Preface
Chapter 1 Introduction to Veterinary Pharmacy
1.1 Introduction
1.1.1 History
1.2 Veterinary Pharmacy Professional Organizations
1.2.1 Society of Veterinary Hospital Pharmacists
1.2.2 International College of Veterinary Pharmacy
1.2.3 American College of Veterinary Pharmacists
1.3 Veterinary Organizations with Pharmacological Expertise
1.3.1 The American Academy of Veterinary Pharmacology and Therapeutics (AAVPT)
1.3.2 The American College of Veterinary Clinical Pharmacology (ACVCP)
1.4 Impact of Veterinary Pharmacy Practice
1.5 Scope of Pharmacist Involvement in Veterinary Medicine
1.5.1 Veterinary Teaching Hospitals
1.5.2 Veterinary Specialty Referral Centers
1.5.3 "Community" Veterinary Pharmacies
1.5.4 Industry (Pharmaceutical and Agricultural)
1.5.5 Government Sectors (FDA, CDC, NIH, and Disaster Relief)
1.5.6 Animal Poison Prevention and Consultation
1.6 Veterinary Pharmacy Practice Considerations
1.6.1 Basic Considerations
1.6.2 Veterinary Drug Law
1.6.3 Regulations for Drugs Intended for Food-Producing Animals
1.6.4 Regulations for Drug Use in Companion Animals
1.6.5 Veterinary Drug Compounding
1.6.6 Veterinary Adverse Drug Event Reporting
1.6.7 Veterinary Terminology
1.6.8 Drug Administration
1.6.9 Veterinary-Only Drugs
1.6.10 Monitoring Veterinary Patients for Response to Drug Therapy
1.7 Species Specifics
1.7.1 Anatomy
1.7.2 Physiology
1.7.3 Metabolic Capacity
1.7.4 Pharmacogenomics
1.8 Critical Evaluation of Published Veterinary Literature
1.9 Veterinary Pharmacy Information Resources
1.9.1 Veterinary Drug Information Reference Handbooks
1.9.2 Veterinary Journals
1.10 Veterinary Pharmacy Educational Core
1.11 Summary
References
Chapter 2 Regulation of Veterinary Pharmaceuticals
2.1 Introduction
2.1.1 FDA Center for Veterinary Medicine Organizational Structure
2.2 Veterinary Drug Approval Process
2.2.1 Regulatory Framework
2.2.2 Original Application or Pioneer Drugs
2.2.3 Generic Animal Drugs
2.3 Prescription versus Over-the-Counter Status of Animal Drugs
2.3.1 Animal Feeds
2.3.2 Extra-Label Drug Use in Veterinary Patients
2.4 Nutritional Supplements for Veterinary Patients
2.5 Compounded Drugs for Veterinary Patients
2.6 Conclusion
Abbreviations
Chapter 3 Compounding for Animals
3.1 Introduction
3.2 Definitions of Compounding
3.3 Scope of Veterinary Compounding
3.4 Potential Benefits of Compounded Drugs for Veterinary Patients
3.5 Risks Associated with the Use of Compounded Drugs in Animals
3.6 Current Regulatory Environment for Compounding
3.7 Compounding for Food-Producing Animals
3.8 Compounding Controlled Substances
3.9 Quality Standards for Compounded Drugs
3.9.1 USP Compounding Standards
3.10 Component Considerations for Veterinary Patients
3.11 Sourcing Verified Formulas for Compounds
3.12 Compounded Veterinary Dosage Forms and Compounding Techniques
3.12.1 Oral Suspensions
3.12.2 Oral Pastes
3.12.3 Oral Capsules
3.12.4 Medicated Treats
3.12.5 Transdermal Gels
3.13 Quality Assurance for Compounded Drugs
3.14 Animal-Friendly Dispensing and Administration Devices for Compounded Drugs
3.15 Owner Counseling Points for Compounded Veterinary Drugs
3.16 Adverse Event Reporting for Compounded Drugs
3.17 Veterinary Compounding Training Opportunities
3.18 Summary
References
Chapter 4 Comparative Pharmacokinetics and Pharmacodynamics
4.1 Introduction
4.2 Pharmacokinetic Species Differences
4.2.1 Species Differences in Drug Absorption
4.2.2 Species Differences in Drug Distribution
4.2.3 Species Differences in Drug Metabolism
4.2.4 Species Differences in Excretion
4.3 Pharmacodynamic Species Differences
References
Chapter 5 Breed Differences and Pharmacogenetics
5.1 Introduction
5.1.1 P-Glycoprotein Polymorphisms
5.1.2 Pharmacogenetics of Oral Drug Absorption
5.1.3 Pharmacogenetics of Drug Distribution
5.1.4 Pharmacogenetics of Drug Metabolism
5.1.5 Pharmacogenetics of Drug Excretion
5.1.6 Pharmacogenetics of Renal Excretion
5.1.7 Pharmacogenetics of Drug Receptors and Targets
5.1.8 Pharmacogenetics and Idiosyncratic Reactions
5.1.9 Phenoconversion
5.1.10 Veterinary Pharmacogenetic Testing
Abbreviations
References
Chapter 6 Human Over-the-Counter (OTC) Products: Precautions for Veterinary Patients
6.1 Analgesics
6.1.1 Acetaminophen
6.1.2 Nonsteroidal Anti-Inflammatory Drugs
6.1.3 Phenazopyridine (Urinary Analgesic)
6.2 Allergy, Cough, Cold, and Flu Medications
6.2.1 Antihistamines (H1 Receptor Antagonists)
6.2.2 Decongestants
6.3 Cough Suppressants
6.4 Gastrointestinal Medications
6.4.1 Antacids
6.4.2 Histamine-2 Receptor Antagonists
6.4.3 Proton Pump Inhibitors
6.4.4 Antidiarrheals
6.5 Vitamin and Mineral Supplements
6.5.1 Iron
6.5.2 Vitamin D
6.6 Xylitol-Containing Products
6.7 Diaper Rash Creams
6.8 Nicotine-Containing Medications
6.9 Sleep Aids
6.10 Miscellaneous Products
6.10.1 5-Hydroxytryptophan
6.10.2 Caffeine (Guarana)
6.10.3 Methionine
6.10.4 Tea Tree Oil
6.10.5 Topical and Local Anesthetics
6.10.6 Eye Drops and Nasal Sprays
6.10.7 Thermometers - Batteries
6.10.8 Thermometers - Mercury
6.11 Decontamination Procedures
6.11.1 Dermal Exposures
6.11.2 Ocular Exposures
6.11.3 Inhalant Exposures
6.11.4 Exposure by Oral Ingestion
References
Chapter 7 Pharmacotherapy of Parasitic Disease
7.1 Comparative Aspects of Parasitic Infections
7.2 Diagnostic Testing
7.2.1 Internal Parasites
7.2.2 External Parasites
7.3 Treatment Considerations for Common Internal Parasitic Diseases
7.3.1 Roundworms
7.3.2 Hookworms
7.3.3 Whipworms
7.3.4 Heartworms
7.3.5 Tapeworms
7.3.6 Miscellaneous
7.4 Treatment Considerations for Common External Parasitic Diseases
7.4.1 Fleas
7.4.2 Ticks
7.4.3 Mites
7.4.4 Miscellaneous External Parasites
7.5 Classes of Antiparasitic Drugs Used in Small Animals
7.5.1 Amitraz
7.5.2 Benzimidazoles
7.5.3 DEET
7.5.4 Docusate
7.5.5 Emodepside
7.5.6 Fipronil
7.5.7 Insect Growth Regulators
7.5.8 Isoquinolines
7.5.9 Isoxazoline Ectoparasiticides
7.5.10 Levamisole
7.5.11 Lime Sulfur
7.5.12 Limonene
7.5.13 Macrocyclic Lactones
7.5.14 Neonicotinoids
7.5.15 Organophosphates and Carbamates
7.5.16 Piperazine
7.5.17 Pyrethrins and Synthetic Pyrethroids
7.5.18 Rotenone
7.5.19 Tetrahydropyrimidines (Pyrantel)
7.6 Unique Aspect of Parasiticide Dosing
References
Chapter 8 Pain Management in Veterinary Species
8.1 Comparative Aspects of Pain
8.2 Diagnostic Testing
8.3 Pharmacological Treatment of Pain
8.3.1 NSAIDs and Acetaminophen
8.3.2 Opioids
8.3.3 Tramadol
8.3.4 Amantadine
8.3.5 Gabapentinoids
8.3.6 Tricyclic Antidepressants
8.3.7 Local Anesthetics
8.4 Adverse Effects in Veterinary Species
8.4.1 NSAIDs and Acetaminophen
8.4.2 Opioids
8.4.3 Tramadol
8.4.4 Amantadine
8.4.5 Gabapentinoids
8.4.6 Tricyclic Antidepressants
8.5 Nutritional Supplements for Managing Pain
References
Chapter 9 Pharmacotherapeutics of Infectious Disease
9.1 Introduction
9.2 Comparative Aspects of Infectious Diseases
9.3 Antibiotics (Antibacterial Agents)
9.3.1 Important Terminology
9.3.2 Relationship of MIC to Clinical Outcome (Pharmacokinetic-Pharmacodynamic Relationships)
9.3.3 Antibacterial Drug Resistance
9.3.4 Susceptibility Testing
9.4 Overview of Major Antibiotics Classes
9.4.1 Beta-Lactam Antibiotics
9.4.2 Aminoglycosides
9.4.3 Tetracyclines
9.4.4 Amphenicols
9.4.5 Macrolide Antibiotics
9.4.6 Lincosamides: Clindamycin and Lincomycin
9.4.7 Oxazolidinones: Linezolid (Zyvox)
9.4.8 Potentiated Sulfonamide Combinations
9.4.9 Fluoroquinolone Antimicrobials
9.4.10 Metronidazole and Related Nitroimidazoles
9.4.11 Rifamycins: Rifampin
9.5 Antifungal Drugs
9.5.1 Griseofulvin
9.5.2 Amphotericin B
9.5.3 Azole Antifungal Drugs
9.5.4 Terbinafine
9.5.5 Topical Agents for Treating Malassezia and Dermatophytes
9.6 Antiviral Drugs
9.6.1 Systemic Antiviral Agents
9.7 Antiprotozoal Drugs
9.7.1 Nitroimidazoles
9.7.2 Pentavalent Antimonials
9.7.3 Benzimidazoles
9.7.4 Aminoglycosides
9.7.5 Tetracyclines
9.7.6 Hydroxyquinolones
9.7.7 Thiamine Analogs
9.7.8 Triazine Derivatives
9.7.9 Sulfonamides
9.7.10 Lincosamides
9.7.11 Macrolides
9.7.12 Chloroquine
9.7.13 Diminazene Diaceturate
9.7.14 Imidocarb Dipropionate
9.7.15 Nitazoxanide
References
Chapter 10 Cardiovascular Pharmacotherapeutics
10.1 Comparative Aspects of Cardiovascular Disease
10.1.1 Congenital Heart Diseases
10.1.2 Degenerative Valve Disease
10.1.3 Cardiomyopathies
10.1.4 Thyrotoxic Heart Disease
10.1.5 Hypertensive Diseases
10.1.6 Arrhythmic Diseases
10.1.7 Thromboembolic Diseases
10.1.8 Infectious Cardiovascular Diseases
10.2 Drug-Induced Cardiovascular Disease
10.3 Cardiovascular Drug Pharmacogenomics
10.4 Diagnostic Testing
10.5 Pharmacological Treatment of Common Diseases
10.5.1 Heartworm Disease Prevention and Treatment
10.5.2 Delay Onset of Congestive Heart Failure
10.5.3 Congestive Heart Failure
10.5.4 Systemic Hypertension
10.5.5 Pulmonary Hypertension
10.5.6 Thyrotoxic Heart Disease
10.5.7 Arrhythmias
10.5.8 Thrombosis Risk Reduction
10.5.9 Endocarditis and Myocarditis
10.6 Adverse Effects of Cardiovascular Drugs in Veterinary Species
10.6.1 Heartworm Preventatives
10.6.2 Adulticide Heartworm Treatment
10.6.3 Doxycycline
10.6.4 Heart Failure Treatment
10.6.5 Antiarrhythmics
10.6.6 Antithrombotics
10.7 Nutritional Supplements for Veterinary Cardiovascular Diseases
10.7.1 Omega-3 Fatty Acids
10.7.2 CoEnzyme Q (Co-Q10)
10.7.3 Taurine
10.7.4 l-Carnitine
10.8 FDA-Approved Veterinary Drug Products with No Human Drug Equivalent
Abbreviations
References
Chapter 11 Respiratory Pharmacotherapeutics
11.1 Comparative Aspects of Respiratory Disease
11.1.1 Drug-Induced Pulmonary Disease
11.2 Diagnostic Testing
11.3 Pharmacological Treatment of Common Diseases
11.3.1 Feline Asthma
11.3.2 Canine Chronic Bronchitis
11.3.3 Tracheal Collapse
11.3.4 Rhinitis
11.3.5 Pulmonary Hypertension
11.4 Adverse Drug Effects in Veterinary Species
11.4.1 Corticosteroids
11.4.2 Bronchodilators
11.4.3 Antitussives
11.4.4 Decongestants
11.5 Nutritional Supplements for Veterinary Respiratory Diseases
11.6 FDA-Approved Veterinary Drug Products with No Human Drug Equivalent
Abbreviations
References
Chapter 12 Gastrointestinal, Hepatic, and Pancreatic Pharmacotherapeutics
12.1 Comparative Aspects of Gastrointestinal Disease
12.2 Specific GI Diseases of Importance in Small-Animal Veterinary Medicine
12.2.1 Drug-Induced GI, Hepatic, and Pancreatic Disease
12.3 Diagnostic Testing
12.4 Pharmacological Treatment of Common Diseases
12.4.1 Cholinergic Drugs Most Likely to Be Prescribed
12.4.2 Acid Suppression Drugs Most Likely to Be Prescribed
12.4.3 Prokinetic Drugs Most Likely to Be Prescribed
12.4.4 Antiemetics Most Likely to Be Prescribed
12.4.5 Gastroprotectant Drugs Most Likely to Be Prescribed
12.4.6 Antiparasite Drugs Most Likely to Be Prescribed (See Also Chapter 7)
12.4.7 Antidiarrheal Drugs Most Likely to Be Prescribed
12.4.8 Pancreatic Enzyme Supplements Most Likely to Be Prescribed
12.4.9 Antibacterial Drugs Most Likely to Be Prescribed
12.4.10 Anti-Inflammatory/Immunosuppressive Drugs Most Likely to Be Prescribed
12.4.11 Osmotic Laxative Drugs Most Likely to Be Prescribed
12.4.12 Hepatoprotective Drugs Most Likely to Be Prescribed
12.5 Adverse Drug Effects in Veterinary Species
12.5.1 Pyridostigmine
12.5.2 Metronidazole
12.5.3 Metoclopramide
12.5.4 Loperamide
12.5.5 Sulfasalazine, Mesalamine, and Olsalazine
12.5.6 Misoprostol
12.5.7 Azathioprine
12.5.8 Cyclosporine
12.5.9 Bismuth Subsalicylate
12.5.10 Corticosteroids
12.6 Nutritional Supplements for Veterinary Gastrointestinal Diseases
12.7 FDA-Approved Veterinary Drug Products with No Human Drug Equivalent
Abbreviations
Bibliography
Chapter 13 Pharmacotherapy of Renal and Lower Urinary Tract Disease
Part I Renal Disease
13.1 Comparative Aspects of Renal Disease
13.2 Drug-Induced Renal Disease
13.3 Diagnostic Testing
13.4 Pharmacological Treatment of Common Renal Diseases
13.4.1 Acute Kidney Injury
13.4.2 Chronic Kidney Disease
13.4.3 Protein-Losing Glomerulonephropathy
13.4.4 Renal Tubular Disorders
13.4.5 Disorders of Water Metabolism
13.4.6 Nephroureterolithiasis
13.4.7 Neoplasia
13.5 Adverse Drug Effects in Veterinary Species
13.6 Nutritional Supplements for Veterinary Renal Disease
13.7 FDA-Approved Veterinary Drug Products with No Human Drug Equivalent
Part II Pharmacotherapeutics of Lower Urinary Tract Disease
13.8 Comparative Aspects of Lower Urinary Tract Disease
13.9 Drug-Induced Lower Urinary Tract Disease
13.10 Diagnostic Testing
13.11 Pharmacological Treatment of Common Diseases
13.11.1 Urolithiasis
13.11.2 Infectious Cystitis
13.11.3 Idiopathic Cystitis
13.11.4 Micturition Disorders
13.11.5 Prostate Disease
13.12 Adverse Effects in Veterinary Species
13.13 Nutritional Supplements for Veterinary Lower Urinary Tract Disease
13.13.1 Urinary Tract Infection
13.13.2 Feline Idiopathic Cystitis
13.13.3 Benign Prostatic Hyperplasia
13.13.4 Miscellaneous
13.14 FDA-Approved Veterinary Drug Products with No Human Drug Equivalent
References
Chapter 14 Pharmacotherapeutics of Immune-Mediated Disease
14.1 Comparative Aspects of Immune-Mediated Disease
14.1.1 Immune-Mediated Cytopenias
14.1.2 Immune-Mediated Arthritides
14.1.3 Inflammatory Bowel Disease
14.1.4 Systemic Lupus Erythematosus
14.1.5 Drug-Induced Immune-Mediated Disease
14.2 Diagnostic Testing
14.3 Pharmacological Treatment of Common Immune-Mediated Diseases
14.3.1 Corticosteroids
14.3.2 Cyclosporine A, Modified
14.3.3 Azathioprine
14.3.4 Chlorambucil
14.3.5 Mycophenolate Mofetil
14.3.6 Leflunomide
14.4 Adverse Drug Effects of Immunosuppressive Drugs in Veterinary Species
14.4.1 Corticosteroids
14.4.2 Cyclosporine A, Modified
14.4.3 Azathioprine
14.4.4 Chlorambucil
14.4.5 Mycophenolate Mofetil
14.4.6 Leflunomide
14.5 Nutritional Supplements for Immune-Mediated Disease
Abbreviations
References
Chapter 15 Endocrine Pharmacotherapeutics
15.1 Comparative Aspects of Endocrine Disease
15.1.1 Diseases of the Thyroid Gland
15.1.2 Diseases of the Adrenal Gland
15.1.3 Diseases of the Endocrine Pancreas
15.1.4 Drug-Induced Endocrine Disease
15.2 Diagnostic Testing
15.3 Pharmacological Treatment of Common Diseases
15.3.1 Canine Hypothyroidism
15.3.2 Feline Hyperthyroidism
15.3.3 Canine Hyperadrenocorticism
15.3.4 Canine Hypoadrenocorticism
15.3.5 Diabetes Mellitus
15.4 Adverse Drug Effects in Veterinary Species
15.5 Nutritional Supplements for Veterinary Endocrine Diseases
15.6 FDA-Approved Veterinary Drug Products with No Human Drug Equivalent
Abbreviations
References
Chapter 16 Behavioral Pharmacotherapeutics
16.1 Comparative Aspects of Behavior Disorders
16.2 Diagnostic Testing
16.3 Pharmacological Treatment of Common Behavioral Disorders
16.3.1 Medications Used Most Frequently to Treat Behavioral Conditions
16.4 Use of Behavior-Modifying Drugs in Animals with Concurrent Disease Processes
16.4.1 Thyroid Disease
16.4.2 Pain Management
16.4.3 Seizures
16.4.4 Drug Interactions Involving Canine and Feline Cytochrome P450 (CYP) Enzymes
16.5 Adverse Effects of Behavior-Modifying Drugs in Veterinary Species
16.5.1 Serotonin Syndrome
16.5.2 Liver and Kidney Function
16.5.3 Benzodiazepines and Excessive Sedation
16.6 Nutritional Supplements for Behavioral Disorders
16.7 FDA-Approved Veterinary Drug Products for Treating Behavioral Disorders
Abbreviations
References
Chapter 17 Pharmacotherapeutics of Neurological Disorders
17.1 Comparative Aspects of Neurological Disorders
17.2 Diagnostic Testing
17.3 Pharmacotherapy of Epilepsy
17.3.1 Phenobarbital
17.3.2 Primidone
17.3.3 Potassium Bromide (KBr)
17.3.4 Levetiracetam
17.3.5 Zonisamide
17.3.6 Imepitoin
17.4 Adverse Drug Effects in Veterinary Species
17.4.1 Phenobarbital
17.4.2 Primidone
17.4.3 Potassium Bromide
17.4.4 Zonisamide
17.4.5 Imepitoin
17.5 Nutritional Supplements for Epilepsy in Veterinary Species
Abbreviations
Further Reading
Chapter 18 Dermatologic Pharmacotherapeutics
18.1 Comparative Aspects of Atopic Dermatitis
18.2 Diagnostic Testing
18.3 Pharmacological Treatment of Atopic Dermatitis
18.3.1 Corticosteroids: Canine AD
18.3.2 Corticosteroids: Feline AD
18.3.3 Corticosteroid Dosing Guidelines
18.4 Antihistamines (H1)
18.5 Tricyclic Antidepressants
18.6 Immunosuppressants
18.6.1 Modified Cyclosporine
18.7 Oclacitinib
18.8 Monoclonal Antibody (mAb) Therapy
18.9 Immunotherapy (Hyposensitization)
18.10 Topical Medications
18.10.1 Topical Corticosteroids
18.10.2 Tacrolimus 0.1% Topical Ointment
18.11 Nutritional Supplements for Veterinary Atopic Dermatitis
18.12 Pharmacotherapeutics of "Autoimmune" Dermatologic Disease
18.12.1 Comparative Aspects of Pemphigus Foliaceus
18.12.2 Comparative Aspects of Discoid Lupus Erythematosus (DLE)
18.12.3 Comparative Aspects of Dermatomyositis (DMS)
18.13 FDA-Approved Veterinary Drug Products with No Human Drug Equivalent
Abbreviations
References
Chapter 19 Ophthalmic Pharmacotherapeutics
19.1 Comparative Aspects of Ophthalmic Disease
19.1.1 Drug-Induced Ophthalmic Disease
19.2 Diagnostic Testing
19.3 Pharmacological Treatment of Common Eye Diseases
19.3.1 Glaucoma
19.3.2 Conjunctivitis
19.3.3 Corneal Diseases
19.3.4 Uveitis
19.4 Adverse Drug Effects in Veterinary Species
19.4.1 Systemic Absorption of Topically Administered Drugs
19.4.2 Topical Ophthalmic Drugs and Visual Disturbances
19.4.3 Topical Corticosteroids
19.4.4 Topical Carbonic Anhydrase Inhibitors
19.4.5 Topical Prostaglandins
19.4.6 Topical Beta Adrenergic Antagonists
19.4.7 Topical NSAIDs
19.5 Nutritional Supplements for Veterinary Ophthalmic Diseases
19.6 FDA-Approved Veterinary Drug Products for Ophthalmic Diseases
References
Chapter 20 Pharmacotherapeutics of Cancer
20.1 Comparative Aspects of Cancer
20.2 Diagnostic Testing
20.3 Pharmacotherapy of Cancer
20.3.1 Alkylating Agents
20.4 Adverse Effects of Anticancer Drugs in Veterinary Species
20.4.1 Common Adverse Drug Reactions
20.4.2 Specific Adverse Reactions by Drug Class
20.5 Nutritional Supplements for Neoplastic Diseases in Veterinary Patients
Abbreviations
References
Chapter 21 Introduction to Equine Pharmacotherapy
21.1 Drug Absorption, Distribution, Metabolism, and Elimination in the Horse
21.1.1 Absorption
21.1.2 Distribution
21.1.3 Metabolism
21.1.4 Elimination
21.2 Drugs Commonly Prescribed for Horses
21.2.1 Antibiotics
21.2.2 Anti-inflammatory Drugs
21.2.3 Anti-ulcer Drugs
21.2.4 Miscellaneous Drugs
21.3 Drugs Commonly Compounded for Horses
21.4 Adverse Effects of Selected Drugs Specific to Horses
21.4.1 Antibiotics and Diarrhea
21.4.2 Corticosteroids and Laminitis
21.4.3 NSAIDS and Right Dorsal Colitis
21.5 Regulatory Drug Restrictions for Performance Horses
21.6 Nutritional Supplements Used in Horses
References
Chapter 22 Introduction to Food Animal Pharmacotherapy
22.1 Introduction
22.2 Food Safety and Withdrawal Times
22.3 Drug Absorption, Distribution, Metabolism, and Elimination in Food Animals
22.3.1 Absorption
22.3.2 Distribution
22.3.3 Metabolism
22.3.4 Excretion
22.3.5 Other
22.4 Drugs Commonly Prescribed for Food Animals
22.4.1 Antibiotics
22.4.2 Antiparasitics
22.4.3 NSAIDs
22.5 Dispensing Considerations
22.5.1 Labeling
22.5.2 Veterinary Feed Directives
22.5.3 Prohibited Drugs
22.5.4 Substitutions
22.5.5 Compounding
22.6 Organic Production
22.7 Summary
References
Chapter 23 Pharmacotherapeutics for Nontraditional Pets
Section 1: Rabbits, Birds, and Pet Rodents
23.1 Introduction
23.2 Rabbit Pharmacotherapeutics
23.2.1 Comparative Aspects of Rabbit Diseases
23.2.2 Diagnostic Testing of Pet Rabbits
23.2.3 Pharmacologic Treatment of Common Rabbit Diseases
23.2.4 Adverse Drug Effects in Rabbits
23.2.5 Nutritional Supplements in Rabbits
23.3 Avian Pharmacotherapeutics
23.3.1 Comparative Aspects of Avian Diseases
23.3.2 Diagnostic Testing of Avian Pets
23.3.3 Pharmacologic Treatment of Common Avian Diseases
23.3.4 Adverse Drug Effects in Avian Patients
23.3.5 Nutritional Supplements in Avian Patients
23.4 Rodent Pharmacotherapeutics
23.4.1 Comparative Aspects of Guinea Pig and Rodent Diseases
23.4.2 Diagnostic Testing of Pet Rodents
23.4.3 Pharmacologic Treatment of Common Rodent Diseases
23.4.4 Adverse Drug Effects in Rodents
23.4.5 Nutritional Supplements in Pet Rodents
Section 2: Ferrets and Reptiles
23.5 Ferret Pharmacotherapeutics
23.5.1 Comparative Aspects of Ferret Diseases
23.5.2 Diagnostic Testing of Pet Ferrets
23.5.3 Pharmacologic Treatment of Common Ferret Diseases
23.5.4 Adverse Drug Effects in Ferrets
23.5.5 Nutritional Supplements in Ferrets
23.6 Reptile Pharmacotherapeutics
23.6.1 Comparative Aspects of Reptile Diseases
23.6.2 Diagnostic Testing of Pet Reptiles
23.6.3 Pharmacologic Treatment of Common Reptile Diseases
23.6.4 Adverse Drug Effects in Reptiles
23.6.5 Nutritional Supplements in Reptiles
References
Chapter 24 Special Considerations for Service, Working, and Performance Animals
24.1 Introduction
24.2 The Role of Special Senses for Service Dogs and Working Dogs
24.2.1 Drug-Induced Injury to the Special Senses
24.3 Performance Animals
Abbreviations
References
Chapter 25 Counseling for Owners of Veterinary Patients
25.1 Introduction
25.2 ASHP List of Contents for an Education and Counseling Session - Veterinary Perspectives
25.2.1 The Medication's Trade Name, Generic Name, Common Synonym, or Other Descriptive Name(s) and, When Appropriate, Its Therapeutic Class and Efficacy
25.2.2 The Medication's Use and Expected Benefits and Action. This May Include Whether the Medication Is Intended to Cure a Disease, Eliminate or Reduce Symptoms, Arrest or Slow the Disease Process, or Prevent the Disease or a Symptom
25.2.3 The Medication's Expected Onset of Action, and What to Do if the Action Does Not Occur
25.2.4 The Medication's Route, Dosage Form, Dosage, and Administration Schedule (Including Duration of Therapy)
25.2.5 Directions for Preparing and Using or Administering the Medication. This May Include Adaptation to Fit Patients' Lifestyles or Work Environments
25.2.6 Action to Be Taken in Case of a Missed Dose
25.2.7 Precautions to Be Observed during the Medication's Use or Administration and the Medication's Potential Risks in Relation to Benefits. For Injectable Medications and Administration Devices, Concern about Latex Allergy May Be Discussed
25.2.8 Potential Common and Severe Adverse Effects That May Occur, Actions to Prevent or Minimize Their Occurrence, and Actions to Take if They Occur, Including Notifying the Prescriber, Pharmacist, or Other Healthcare Provider
25.2.9 Techniques for Self-Monitoring of Pharmacotherapy
25.2.10 Potential Drug-Drug (Including Nonprescription), Drug-Food, and Drug-Disease Interactions or Contraindications
25.2.11 The Medication's Relationships to Radiologic and Laboratory Procedures (e.g. Timing of Doses and Potential Interference with Interpretations of Results)
25.2.12 Prescription Refill Authorizations and the Process for Obtaining Refills
25.2.13 Instructions for 24-Hour Access to a Pharmacist
25.2.14 Proper Storage of the Medication
25.2.15 Proper Disposal of Contaminated or Discontinued Medications and Used Administration Devices
25.2.16 Any Other Information Unique to an Individual Patient or Medication
References
Appendix A Veterinary Teaching Hospital Pharmacy Contact Information
Appendix B Directional Anatomical Terminology of Bipeds Quadrupeds
Appendix C Vital signs and potential monitoring parameters for dogs, cats, horses, and ferrets
OtherMonitoring Parameters
Appendix D Auxiliary Labels Cross-referenced by Drug
Appendix E FDA Adverse Event Reporting Form
Appendix F Veterinary Pharmacogenetics Testing Laboratories with Counseling Expertise
Appendix G Therapeutic Drug Monitoring Laboratories
Appendix H Canine and Feline Body Surface Area Conversion Tables
Appendix I Zoonotic Diseases of Dogs, Cats, and Horses
Index
EULA

Inhalt (PDF)

Systemvoraussetzungen

Als PDF speichern Als Link merken